Good afternoon :)
Place Order
Add to Watchlist

Jagsonpal Pharmaceuticals Ltd

JAGSNPHARM Share Price

227.462.25% (-5.24)

JAGSNPHARM Share Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,545 cr, stock is ranked 1,194
High RiskStock is 4.16x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,545 cr, stock is ranked 1,194
High RiskStock is 4.16x as volatile as Nifty

JAGSNPHARM Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
29.538.240.86%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.166.420.53%

JAGSNPHARM Analyst Ratings & Forecast

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

JAGSNPHARM Company Profile

Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.

JAGSNPHARM Similar Stocks (Peers)

Compare with peers 
PE Ratio
46.14
1Y Return
21.03%
Buy Reco %
88.24
PE Ratio
30.47
1Y Return
10.45%
Buy Reco %
72.73
PE Ratio
68.14
1Y Return
24.10%
Buy Reco %
68.00
PE Ratio
55.22
1Y Return
7.72%
Buy Reco %
81.25
PE Ratio
17.88
1Y Return
4.82%
Buy Reco %
46.67
Compare with Peers
JAGSNPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly

JAGSNPHARM Stock Summary · January 2025

Jagsonpal Pharmaceuticals Limited has demonstrated robust financial performance, achieving a remarkable 57% year-on-year revenue growth in Q3 FY25, bolstered by strategic initiatives and operational efficiencies. Despite facing challenges in certain product lines due to intense market competition and counterfeit issues, the company is optimistic about future growth, targeting a 12% to 14% increase in top-line revenue. The integration of recent acquisitions is progressing well, contributing positively to profitability, while a focus on enhancing sales force productivity remains critical. With a strong emphasis on cash utilization for strategic growth and potential acquisitions, the company is committed to maintaining its leadership in the gynae segment, which constitutes half of its revenues.

Key Points on Jagsnpharm Stock
JAGSNPHARM Stock Growth Drivers
5
  • Strong Financial Performance

    Jagsonpal Pharmaceuticals Limited reported significant financial achievements for Q3 FY25, including revenues of approximately INR

  • Strategic Corporate Developments

    The company completed a strategic divestment of its Faridabad facility for INR 41 crores, contributing

JAGSNPHARM Stock Challenges
4
  • Performance Challenges of Divatrone

    Divatrone is facing significant performance challenges in a hyper-competitive market, leading to a notable drop

  • Concerns Over ESOP Costs

    The company is experiencing fluctuations in ESOP costs, with the current quarter's expense reported at

JAGSNPHARM Forecasts

Price

Revenue

Earnings

JAGSNPHARM

Income

Balance Sheet

Cash Flow

JAGSNPHARM Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 5.31%, vs industry avg of 9.04%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.08% to 0.06%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 25.48%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue144.15157.14126.99168.26161.10192.34221.01242.44217.98284.73
Raw Materialssubtract65.3567.3465.1953.4354.9475.5083.3588.0476.08211.91
Power & Fuel Costsubtract2.262.121.001.410.640.520.470.290.17
Employee Costsubtract37.8440.9541.8846.6150.3753.9857.6865.1861.80
Selling & Administrative Expensessubtract26.5830.1927.5632.2338.3431.8842.5041.6641.09
Operating & Other expensessubtract-0.34-2.502.0123.815.756.998.5610.856.50
Depreciation/Amortizationsubtract3.091.990.321.021.131.091.531.211.666.22
Interest & Other Itemssubtract5.302.640.660.750.510.510.290.410.810.93
Taxes & Other Itemssubtract0.832.53-0.081.781.544.827.788.097.4113.35
EPS0.491.81-1.761.101.202.602.884.083.417.92
DPS0.040.040.040.100.200.401.602.002.002.00
Payout ratio0.080.020.090.170.150.560.490.590.25

JAGSNPHARM Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2015

Annual Report Unavailable

FY 2022

Annual report

PDF

Investor Presentation

Feb 22PDF
 

JAGSNPHARM Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Jagsonpal Pharmaceuticals Ltd68.798.240.86%
Sun Pharmaceutical Industries Ltd46.146.580.73%
Cipla Ltd30.474.690.84%
Torrent Pharmaceuticals Ltd68.1416.460.84%

JAGSNPHARM Stock Price Comparison

Compare JAGSNPHARM with any stock or ETF
Compare JAGSNPHARM with any stock or ETF
JAGSNPHARM
Loading...

JAGSNPHARM Shareholdings

JAGSNPHARM Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

JAGSNPHARM Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

JAGSNPHARM Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding67.78%0.00%0.00%2.10%30.11%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

JAGSNPHARM Shareholding History

Dec '23MarJunSepDec '24Mar0.53%0.73%1.10%2.30%2.10%2.10%

JAGSNPHARM Insider Trades & Bulk Stock Deals

Loading...

smallcases containing JAGSNPHARM stock

Looks like this stock is not in any smallcase yet.

JAGSNPHARM Events

JAGSNPHARM Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

JAGSNPHARM has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.86%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.56 every year

Dividends

Corp. Actions

Announcements

Legal Orders

JAGSNPHARM Upcoming Dividends

No upcoming dividends are available

JAGSNPHARM Past Dividends

Cash Dividend

Ex DateEx DateSep 6, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Sep 6, 2024

Cash Dividend

Ex DateEx DateAug 21, 2023

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Aug 21, 2023

Cash Dividend

Ex DateEx DateOct 29, 2021

Interim
Interim | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Oct 29, 2021

Cash Dividend

Ex DateEx DateSep 22, 2021

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 22, 2021

Cash Dividend

Ex DateEx DateSep 22, 2020

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Sep 22, 2020

JAGSNPHARM Stock News & Opinions

Corporate
Jagsonpal Pharmaceuticals allots 39,850 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 39,850 equity shares under ESOP. With this allotment, the paid up equity share capital has increased to Rs. 13,28,76,960 (constituting of 6,64,38,480 equity shares of Rs. 2/- each).Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 11,575 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 11,575 equity shares under ESOP. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,27,74,110 (constituting of 6,63,87,055 equity shares of Rs. 2/- each) to Rs. 13,27,97,260 (constituting of 6,63,98,630 equity shares of Rs. 2/- each). Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 22,150 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 22,150 equity shares of Rs. 2/- each under JPL ESOP 2022, to the eligible employee of the Company, upon exercise of vested options. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,27,29,810 (constituting of 6,63,64,905 equity shares of Rs. 2/- each) to Rs. 13,27,74,112 (constituting of 6,63,87,056 equity shares of Rs. 2/- each).Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Jagsonpal Pharma gains after reporting strong Q3 numbers

Revenue from operations surged 56.7% to Rs 74.03 crore recorded in the quarter ended 31 December 2024. Profit before exceptional items and tax stood at Rs 15.48 in Q3 FY24, steeply higher than Rs 5.27 crore posted in Q3 FY23. The company reported an exceptional item of Rs 23.18 crore during the quarter. The company's operating EBITDA surged by 185% to Rs 171 crore in Q3 FY25, compared to Rs 60 crore recorded in the same quarter last year. The EBITDA margin also improved to 23.1% in Q3 FY25, up from 12.8% in Q3 FY24. On nine-month basis, the company's net profit climbed 158% to Rs 48.78 crore on 27.2% increase in revenue to Rs 210.16 crore in 9M FY25 over 9M FY24. The company reported a strong balance sheet, having concluded the sale of its Faridabad facility for Rs 41 crore, resulting in exceptional income during Q3 FY25. As of 31 December 2024, the company maintains a robust cash balance of Rs 132.1 crore. Regarding its successful acquisition integration, the company stated that the integration of the acquired business is progressing well. Q3 FY25 marks the second full quarter of operations, with performance aligning with expectations. Jagsonpal Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 707.83% in the December 2024 quarter

Net profit of Jagsonpal Pharmaceuticals rose 707.83% to Rs 31.99 crore in the quarter ended December 2024 as against Rs 3.96 crore during the previous quarter ended December 2023. Sales rose 56.74% to Rs 74.03 crore in the quarter ended December 2024 as against Rs 47.23 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales74.0347.23 57 OPM %21.387.18 - PBDT17.905.68 215 PBT15.495.27 194 NP31.993.96 708 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to declare Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 January 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals fixes record date for stock split

Jagsonpal Pharmaceuticals has fixed 08 January 2025 as record date for stock split of the Company such that 1 (one) equity share having face value of Rs. 5/- (Rupees five only) each, fully paid-up, be sub-divided into such number of equity shares having face value of Rs. 2 (Rupee two only) each, fully paid up. Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 31,040 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 31,040 equity shares under ESOP. Consequently, the paid up equity share capital has increased to Rs. 13,27,29,810 (constituting of 2,65,45,962 equity shares of Rs. 5/- each). Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 53.41% in the September 2024 quarter

Net profit of Jagsonpal Pharmaceuticals rose 53.41% to Rs 11.46 crore in the quarter ended September 2024 as against Rs 7.47 crore during the previous quarter ended September 2023. Sales rose 29.15% to Rs 74.69 crore in the quarter ended September 2024 as against Rs 57.83 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales74.6957.83 29 OPM %21.8114.47 - PBDT17.7110.42 70 PBT15.379.96 54 NP11.467.47 53 Powered by Capital Market - Live

6 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to table results

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live

6 months agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) today?

    The share price of JAGSNPHARM as on 29th April 2025 is ₹227.46. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?

    The past returns of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share are
    • Past 1 week: 7.11%
    • Past 1 month: 7.90%
    • Past 3 months: 4.61%
    • Past 6 months: 23.91%
    • Past 1 year: 65.36%
    • Past 3 years: 86.13%
    • Past 5 years: 1970.28%

  3. What are the peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?
  4. What is the dividend yield % of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?

    The current dividend yield of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 0.86.

  5. What is the market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹1545.10 Cr as of 29th April 2025.

  6. What is the 52 week high and low of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?

    The 52-week high of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹328.04 and the 52-week low is ₹110.

  7. What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) stock?

    The P/E (price-to-earnings) ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 68.79. The P/B (price-to-book) ratio is 8.24.

  8. Which sector does Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belong to?

    Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares?

    You can directly buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.